Literature DB >> 24917245

Temporal trends in population-based death rates associated with chronic liver disease and liver cancer in the United States over the last 30 years.

Yuhree Kim1, Aslam Ejaz, Amit Tayal, Gaya Spolverato, John F P Bridges, Robert A Anders, Timothy M Pawlik.   

Abstract

BACKGROUND: The health and economic burden from liver disease in the United States is substantial and rising. The objective of this study was to characterize temporal trends in mortality from chronic liver disease and liver cancer and the incidence of associated risk factors using population-based data over the past 30 years.
METHODS: Population-based mortality data were obtained from the National Vital Statistics System, and population estimates were derived from the national census for US adults (aged >45 years). Crude death rates (CDRs), age-adjusted death rates (ADRs), and average annual percentage change (AAPC) statistics were calculated.
RESULTS: In total, 690,414 deaths (1.1%) were attributable to chronic liver disease, whereas 331,393 deaths (0.5%) were attributable to liver cancer between 1981 and 2010. The incidence of liver cancer was estimated at 7.1 cases per 100,000 population. Mortality rates from chronic liver disease and liver cancer increased substantially over the past 3 decades, with ADRs of 23.7 and 16.6 per 100,000 population in 2010, respectively. The AAPC from 2006 to 2010 demonstrated an increased ADR for chronic liver disease (AAPC, 1.5%; 95% confidence interval, 0.3%-2.8%) and liver cancer (AAPC, 2.6%; 95% confidence interval, 2.4%-2.7%).
CONCLUSIONS: A comprehensive approach that involves primary and secondary prevention, increased access to treatment, and more funding for liver-related research is needed to address the high death rates associated with chronic liver disease and liver cancer in the United States.
© 2014 American Cancer Society.

Entities:  

Keywords:  chronic liver disease; epidemiology; liver cancer; mortality

Mesh:

Year:  2014        PMID: 24917245      PMCID: PMC4316688          DOI: 10.1002/cncr.28843

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  51 in total

1.  Permutation tests for joinpoint regression with applications to cancer rates.

Authors:  H J Kim; M P Fay; E J Feuer; D N Midthune
Journal:  Stat Med       Date:  2000-02-15       Impact factor: 2.373

2.  A prospective study of obesity and cancer risk (Sweden).

Authors:  A Wolk; G Gridley; M Svensson; O Nyrén; J K McLaughlin; J F Fraumeni; H O Adam
Journal:  Cancer Causes Control       Date:  2001-01       Impact factor: 2.506

3.  Age adjustment using the 2000 projected U.S. population.

Authors:  R J Klein; C A Schoenborn
Journal:  Healthy People 2010 Stat Notes       Date:  2001-01

4.  Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials.

Authors:  J M Llovet; J Bustamante; A Castells; R Vilana; M del C Ayuso; M Sala; C Brú; J Rodés; J Bruix
Journal:  Hepatology       Date:  1999-01       Impact factor: 17.425

Review 5.  Updated treatment approach to hepatocellular carcinoma.

Authors:  Josep M Llovet
Journal:  J Gastroenterol       Date:  2005-03       Impact factor: 7.527

6.  3. Sampling variance of standardized mortality rates.

Authors:  N Keyfitz
Journal:  Hum Biol       Date:  1966-09       Impact factor: 0.553

Review 7.  The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective.

Authors:  Alan P Venook; Christos Papandreou; Junji Furuse; Laura Ladrón de Guevara
Journal:  Oncologist       Date:  2010

8.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.

Authors:  Eugenia E Calle; Carmen Rodriguez; Kimberly Walker-Thurmond; Michael J Thun
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

Review 9.  Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures.

Authors:  D Lavanchy
Journal:  J Viral Hepat       Date:  2004-03       Impact factor: 3.728

10.  Long-term survival and prognostic factors in the surgical treatment for intrahepatic cholangiocarcinoma.

Authors:  Yoshikazu Morimoto; Yasuhiro Tanaka; Toshinori Ito; Masaaki Nakahara; Hiroyuki Nakaba; Toshiro Nishida; Masahiro Fujikawa; Toshikazu Ito; Shigetaka Yamamoto; Toru Kitagawa
Journal:  J Hepatobiliary Pancreat Surg       Date:  2003
View more
  21 in total

1.  Why Pursue a Fourth Year in Advanced/Transplant Hepatology?

Authors:  Arpan Mohanty; Brett E Fortune
Journal:  Dig Dis Sci       Date:  2016-07       Impact factor: 3.199

2.  Alcohol Consumption and Chronic Liver Disease Mortality in New Mexico and the United States, 1999-2013.

Authors:  Laura E Tomedi; Jim Roeber; Michael Landen
Journal:  Public Health Rep       Date:  2018-04-17       Impact factor: 2.792

3.  Increasing Burden of Hepatic Encephalopathy Among Hospitalized Adults: An Analysis of the 2010-2014 National Inpatient Sample.

Authors:  Grishma Hirode; Eric Vittinghoff; Robert J Wong
Journal:  Dig Dis Sci       Date:  2019-03-13       Impact factor: 3.199

4.  Biliary tract cancer incidence and trends in the United States by demographic group, 1999-2013.

Authors:  Alison L Van Dyke; Meredith S Shiels; Gieira S Jones; Ruth M Pfeiffer; Jessica L Petrick; Jennifer L Beebe-Dimmer; Jill Koshiol
Journal:  Cancer       Date:  2019-01-15       Impact factor: 6.860

Review 5.  Intrahepatic cholangiocarcinoma: pathogenesis, current staging, and radiological findings.

Authors:  Mohammed Saleh; Mayur Virarkar; Vlad Bura; Raul Valenzuela; Sanaz Javadi; Janio Szklaruk; Priya Bhosale
Journal:  Abdom Radiol (NY)       Date:  2020-11

6.  Surgery for Intermediate and Advanced Hepatocellular Carcinoma: A Consensus Report from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014).

Authors:  Ming-Chih Ho; Kiyoshi Hasegawa; Xiao-Ping Chen; Hiroaki Nagano; Young-Joo Lee; Gar-Yang Chau; Jian Zhou; Chih-Chi Wang; Young Rok Choi; Ronnie Tung-Ping Poon; Norihiro Kokudo
Journal:  Liver Cancer       Date:  2016-09-14       Impact factor: 11.740

7.  A Phase I trial using local regional treatment, nonlethal irradiation, intratumoral and systemic polyinosinic-polycytidylic acid polylysine carboxymethylcellulose to treat liver cancer: in search of the abscopal effect.

Authors:  Andrew N de la Torre; Sohail Contractor; Ismael Castaneda; Charles S Cathcart; Dolly Razdan; David Klyde; Piotr Kisza; Sharon F Gonzales; Andres M Salazar
Journal:  J Hepatocell Carcinoma       Date:  2017-08-07

8.  Influence of ethnicity on the distribution of genetic polymorphisms associated with risk of chronic liver disease in South American populations.

Authors:  Ana Cecilia Pontoriero; Julieta Trinks; María Laura Hulaniuk; Mariela Caputo; Lisandro Fortuny; Leandro Burgos Pratx; Analía Frías; Oscar Torres; Félix Nuñez; Adrián Gadano; Pablo Argibay; Daniel Corach; Diego Flichman
Journal:  BMC Genet       Date:  2015-07-29       Impact factor: 2.797

9.  MicroRNA-378 limits activation of hepatic stellate cells and liver fibrosis by suppressing Gli3 expression.

Authors:  Jeongeun Hyun; Sihyung Wang; Jieun Kim; Kummara Madhusudana Rao; Soo Yong Park; Ildoo Chung; Chang-Sik Ha; Sang-Woo Kim; Yang H Yun; Youngmi Jung
Journal:  Nat Commun       Date:  2016-03-22       Impact factor: 14.919

Review 10.  The Role of Iron and Iron Overload in Chronic Liver Disease.

Authors:  Sandra Milic; Ivana Mikolasevic; Lidija Orlic; Edita Devcic; Nada Starcevic-Cizmarevic; Davor Stimac; Miljenko Kapovic; Smiljana Ristic
Journal:  Med Sci Monit       Date:  2016-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.